JAGUAR HEALTH, INC. Premiums Receivable, Proceeds from Sale of Receivables
JAGUAR HEALTH, INC. (JAGX) reported Premiums Receivable, Proceeds from Sale of Receivables of $776.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-17.
Discontinued › Notes
us-gaap:PremiumsReceivableProceedsFromSaleOfReceivables · last filed 2021-11-17
- JAGUAR HEALTH, INC. premiums receivable, proceeds from sale of receivables for the quarter ending 2020-09-30 was $0.00.
| Period end | Premiums Receivable, Proceeds from Sale of Receivables 3 month | Premiums Receivable, Proceeds from Sale of Receivables 6 month | Premiums Receivable, Proceeds from Sale of Receivables 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | $776.00K 10-Q · filed 2021-11-17 | |
| 2020-06-30 | $776.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |